Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026

The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $7.07 billion in 2025 to $7.47 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing awareness of hereditary cancer syndromes, availability of brca mutation testing, expansion of cancer screening infrastructure, rising use of hormonal therapies, growth of specialized oncology clinics.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to expansion of personalized oncology treatment approaches, increasing adoption of preventive surgeries, growth in targeted and immunotherapy development, rising investments in genetic diagnostics, improved long-term patient monitoring solutions. Major trends in the forecast period include increasing adoption of genetic counselling services, rising use of preventive therapeutic strategies, growing integration of targeted cancer therapies, expansion of risk-based screening programs, enhanced focus on early intervention approaches.

The increasing prevalence of ovarian cancer is expected to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Ovarian cancer is a malignant condition that originates in the ovaries, which are female reproductive organs responsible for egg production and hormone secretion. This rising trend is associated with factors such as longer life expectancy, delayed childbirth, and changing lifestyle patterns. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a genetic disorder that elevates the risk of developing breast, ovarian, and other related cancers. For example, in April 2024, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, approximately 324,603 women worldwide were diagnosed with ovarian cancer in 2022. The annual number of cases is projected to reach nearly half a million by 2050, representing a 55% increase. Consequently, the growing prevalence of ovarian cancer is contributing to the expansion of the hereditary breast and ovarian cancer syndrome treatment market.

Leading companies operating in the hereditary breast and ovarian cancer syndrome treatment market are introducing new treatment approaches, such as comprehensive risk assessment tests, to deliver more reliable services to patients. A comprehensive risk assessment test is a diagnostic tool designed to evaluate an individual’s likelihood of developing a specific disease or experiencing related symptoms. For instance, in February 2023, Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched an innovative comprehensive risk assessment test for breast and ovarian cancer. This test integrates gene mutation analysis for breast and ovarian cancers with hereditary and non-hereditary risk factors, along with the GeneType risk score for both conditions. The approach uniquely combines the identification of 13 key actionable breast and ovarian cancer susceptibility genes with the GeneType testing platform. The newly introduced test is designed for women over the age of 30 who, aside from rare genetic mutations, have an elevated risk of developing breast and ovarian cancer within the general population.

In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation. This collaboration is intended to simplify the genetic testing process, integrate genetic data into routine clinical workflows, and improve personalized healthcare delivery within the Epic user network. Epic Systems Corporation is a US-based platform provider that supports the assessment of patient risk for hereditary cancers, including hereditary breast and ovarian cancer syndrome (HBOC).

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Seagen Inc., Genentech Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Myriad Genetics Inc., Invitae Corporation, Natera Inc., LifeLabs Genetics, Abbott Laboratories.

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hereditary breast and ovarian cancer syndrome treatment market by increasing costs of imported diagnostic reagents, imaging equipment, targeted oncology drugs, and genetic testing technologies. Hospitals and specialty oncology centers in North America and Europe are most affected due to dependence on imported diagnostics and therapeutics, while Asia-Pacific faces cost pressures on advanced cancer care technologies. These tariffs are increasing overall treatment costs and slowing adoption of preventive interventions. However, they are also promoting domestic production of diagnostic kits, regional pharmaceutical manufacturing, and localized oncology research initiatives.

The hereditary breast and ovarian cancer syndrome treatment market research report is one of a series of new reports that provides hereditary breast and ovarian cancer syndrome treatment market statistics, including hereditary breast and ovarian cancer syndrome treatment industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome treatment market share, detailed hereditary breast and ovarian cancer syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome treatment industry. This hereditary breast and ovarian cancer syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hereditary breast and ovarian cancer syndrome (HBO) treatment encompasses the range of medical strategies and interventions used to manage the increased risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. Treatment for hereditary breast and ovarian cancer syndrome aims to either prevent the onset of cancer or enable early detection, when the disease is more responsive to treatment.

The primary treatment options for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counselling, medication, and others. Hormone replacement therapy is generally recommended for short-term use, is estrogen based, and is tailored to address specific acute symptoms in individuals with hereditary breast and ovarian cancer (HBOC) syndrome, particularly those carrying BRCA1 or BRCA2 mutations. Diagnosis is performed using methods such as genetic testing, magnetic resonance imaging (MRI), mammography, and other techniques. Medications may be administered via oral, parenteral, and other routes, and treatment is delivered through hospitals, specialty clinics, homecare settings, and other healthcare facilities.

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.